NGM BIOPHARMACEUTICALS INC's ticker is NGM and the CUSIP is 62921N105. A total of 1 filers reported holding NGM BIOPHARMACEUTICALS INC in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,276 | -56.7% | 1,193,971 | +4.8% | 0.01% | -58.3% |
| Q2 2023 | $2,948 | -22.9% | 1,138,843 | +21.4% | 0.01% | -29.4% |
| Q1 2023 | $3,824 | +31.2% | 938,434 | +61.5% | 0.02% | +21.4% |
| Q4 2022 | $2,914 | -98.6% | 581,223 | +3377.0% | 0.01% | +1300.0% |
| Q2 2022 | $214,000 | -7.0% | 16,716 | +10.3% | 0.00% | 0.0% |
| Q1 2022 | $230,000 | +666.7% | 15,153 | +770.9% | 0.00% | – |
| Q4 2021 | $30,000 | -64.7% | 1,740 | -59.6% | 0.00% | – |
| Q2 2021 | $85,000 | -54.3% | 4,305 | -54.5% | 0.00% | -100.0% |
| Q2 2020 | $186,000 | +181.8% | 9,452 | +76.9% | 0.00% | – |
| Q1 2020 | $66,000 | – | 5,343 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RHO CAPITAL PARTNERS INC | 3,766,666 | $79,175,000 | 44.14% |
| Ponoi II Management, LLC | 1,298,908 | $27,303,000 | 40.46% |
| Column Group LLC | 15,396,116 | $323,626,000 | 36.81% |
| Ponoi Management, LLC | 1,298,908 | $27,303,000 | 24.24% |
| Euclidean Capital LLC | 832,274 | $17,494,000 | 8.50% |
| StepStone Group LP | 1,573,357 | $33,072,000 | 2.14% |
| Octagon Capital Advisors LP | 200,000 | $4,204,000 | 1.04% |
| Redmile Group, LLC | 2,505,118 | $52,658,000 | 0.92% |
| BVF INC/IL | 955,000 | $20,074,000 | 0.78% |
| Boxer Capital, LLC | 500,000 | $10,510,000 | 0.37% |